Amylyx Pharmaceuticals (AMLX) Stock Price, News & Analysis

Company Overview

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $5.09 to $5.39
• 50-Day Range: $2.49 to $7.03
• 52-Week Range: $1.58 to $19.95
• Volume: 934,367 shs
• Average Volume: 2.02 million shs
• Market Capitalization: $358.51 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.43
• Consensus Rating: Moderate Buy

Amylyx Pharmaceuticals Stock Analysis - MarketRank™

Amylyx Pharmaceuticals scored higher than 87% of companies evaluated by MarketBeat, and ranked 152nd out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Amylyx Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, 5 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Amylyx Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Amylyx Pharmaceuticals are expected to grow in the coming year, from ($2.84) to ($1.50) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Amylyx Pharmaceuticals is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Amylyx Pharmaceuticals is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Amylyx Pharmaceuticals has a P/B Ratio of 0.81. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.13% of the float of Amylyx Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Amylyx Pharmaceuticals has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Amylyx Pharmaceuticals has recently increased by 27.72%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: Weak

Dividend Yield

Amylyx Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Amylyx Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.13% of the float of Amylyx Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Amylyx Pharmaceuticals has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Amylyx Pharmaceuticals has recently increased by 27.72%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 0.90

News Sentiment

Amylyx Pharmaceuticals has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Amylyx Pharmaceuticals this week, compared to 6 articles on an average week.

Search Interest

24 people have searched for AMLX on MarketBeat in the last 30 days. This is an increase of 140% compared to the previous 30 days.

MarketBeat Follows

11 people have added Amylyx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 120% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Amylyx Pharmaceuticals insiders have bought 234.24% more of their company's stock than they have sold. Specifically, they have bought $321,200.00 in company stock and sold $96,099.00 in company stock.

Percentage Held by Insiders

11.70% of the stock of Amylyx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

95.84% of the stock of Amylyx Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AMLX Stock Analysis - Frequently Asked Questions

How have AMLX shares performed this year?

Amylyx Pharmaceuticals' stock was trading at $14.72 at the beginning of the year. Since then, AMLX shares have decreased by 64.5% and is now trading at $5.23.
View the best growth stocks for 2024 here.

How were Amylyx Pharmaceuticals' earnings last quarter?

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) issued its quarterly earnings results on Thursday, August, 8th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.38) by $0.35. The business had revenue of ($1.02) million for the quarter, compared to analyst estimates of $18.83 million. Amylyx Pharmaceuticals had a negative trailing twelve-month return on equity of 36.97% and a negative net margin of 17.86%.

When did Amylyx Pharmaceuticals IPO?

Amylyx Pharmaceuticals (AMLX) raised $190 million in an IPO on Friday, January 7th 2022. The company issued 10,000,000 shares at a price of $18.00-$20.00 per share.

Who are Amylyx Pharmaceuticals' major shareholders?

Top institutional investors of Amylyx Pharmaceuticals include abrdn plc (2.90%), Connor Clark & Lunn Investment Management Ltd. (1.29%), Walleye Capital LLC (0.98%) and Alpha Wave Global LP (0.98%). Insiders that own company stock include Morningside Venture Investment, Justin B Klee, Joshua B Cohen, Global Investors Lp Viking, George M Milne Jr, Patrick D Yeramian, Gina Mazzariello and Daphne Quimi.
View institutional ownership trends.

How do I buy shares of Amylyx Pharmaceuticals?

Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Amylyx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Amylyx Pharmaceuticals investors own include Waste Connections (WCN), American Water Works (AWK), AUO (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 11/20/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 2/27/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AMLX
• CUSIP: N/A
• CIK: 1658551
• Web: amylyx.com
• Phone: 617-682-0917
• Fax: N/A
• Employees: 200
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $11.43
• High Stock Price Target: $36.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +118.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 10 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.82)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $49.27 million
• Net Margins: -17.86%
• Pretax Margin: -131.04%
• Return on Equity: -36.97%
• Return on Assets: -29.61%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.55
• Quick Ratio: 4.55

Sales & Book Value

• Annual Sales: $196.49 million
• Price / Sales: 1.82
• Cash Flow: $0.66 per share
• Price / Cash Flow: 7.95
• Book Value: $6.42 per share
• Price / Book: 0.81

Miscellaneous

• Outstanding Shares: 68,548,000
• Free Float: 60,528,000
• Market Cap: $358.51 million
• Optionable: Optionable
• Beta: -0.70